Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.

Summary

In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks. To compare effect (ocular surface damage) and safety of preservative-free Latanoprost/Tafluprost to Benzalkonium chloride-preserved Latanoprost in primary open angle glaucoma or normal tension glaucoma.

Timeline

Start

2018-12-19

Primary completion

2019-12

Completion

2020-02

Drugs

Indications